
Author's Accepted Manuscript

TRANSLATIONAL RESEARCH IN HEPATIC EN-CEPHALOPATHY: NEW DIAGNOSTIC POSSIBI-LITIES AND NEW THERAPEUTIC APPROACHES

Marta Llansola, Carmina Montoliu, Ana Agusti, Vicente Hernandez-Rabaza, Andrea Cabrera-Pastor, Michele Malaguarnera, Belen Gomez-Gimenez, Alma Orts, Raquel Garcia-Garcia, Tiziano Balzano, Lucas Taoro, Vicente Felipo



www.elsevier.com/locate/nhtm

PII: S2307-5023(14)00074-5

DOI: http://dx.doi.org/10.1016/j.nhtm.2014.11.057

Reference: NHTM9

To appear in: New Horizons in Translational Medicine

Cite this article as: Marta Llansola, Carmina Montoliu, Ana Agusti, Vicente Hernandez-Rabaza, Andrea Cabrera-Pastor, Michele Malaguarnera, Belen Gomez-Gimenez, Alma Orts, Raquel Garcia-Garcia, Tiziano Balzano, Lucas TRANSLATIONAL RESEARCH Taoro. Vicente Felipo, IN **HEPATIC** NEW DIAGNOSTIC **POSSIBILITIES ENCEPHALOPATHY:** AND **NEW** THERAPEUTIC APPROACHES, New Horizons in Translational Medicine, http://dx. doi.org/10.1016/j.nhtm.2014.11.057

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

TRANSLATIONAL RESEARCH IN HEPATIC ENCEPHALOPATHY: NEW DIAGNOSTIC POSSIBILITIES AND NEW THERAPEUTIC APPROACHES

Marta Llansola, Carmina Montoliu, Ana Agusti, Vicente Hernandez-Rabaza, Andrea Cabrera-Pastor, Michele Malaguarnera, Belen Gomez-Gimenez, Alma Orts, Raquel Garcia-Garcia, Tiziano Balzano, Lucas Taoro and Vicente Felipo

Laboratory of Neurobiology. Centro de Investigación Príncipe Felipe. Valencia. Spain vfelipo@cipf.es

Focal points:

Benchside

The mechanisms underlying cognitive and motor alterations in minimal hepatic encephalopathy (MHE) are beginning to be clarified in animal models. A number of therapeutic targets have been identified to improve cognitive and motor function in MHE. Also, serum level of 3-nitrotyrosine is the first peripheral biomarker identified for diagnosis of MHE in cirrhotic patients, with high diagnostic accuracy, high sensitivity and specificity.

Bedside:

In the European Union more than 2 million patients with liver cirrhosis show MHE with mild cognitive impairment. MHE is an important, until now underestimated, health, social and economic problem. Early diagnosis and treatment of MHE will significantly improve quality of life and life span of the patients and reduce costs of hospitalization and treatment

Industry

There are no specific treatments for the neurological alterations in MHE. A number of therapeutic targets have been identified in animal models to improve cognitive and motor function in MHE. This is a new market waiting for development of appropriate therapeutic treatments which would improve quality of life and survival of patients. Development of a kit for diagnosis of MHE in clinical practice is pending.

Governments - Regulatory Agencies

Early diagnosis and treatment of MHE will significantly improve quality of life and life span of the patients and reduce costs of hospitalization and treatment. Screening of the presence of MHE in patients with liver diseases will reduce costs.

Download English Version:

https://daneshyari.com/en/article/3815607

Download Persian Version:

https://daneshyari.com/article/3815607

<u>Daneshyari.com</u>